Crystallization and preliminary X-ray diffraction studies of a catechol-O-methyltransferase/inhibitor complex

11Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Inhibitors of the enzyme catechol-O-methyltransferase (COMT) are used as co-adjuvants in the therapy of Parkinson's disease. A recombinant form of the soluble cytosolic COMT from rat has been co-crystallized with a new potent inhibitor, BIA 8-176 [(3,4-dihydroxy-2-nitrophenyl)phenylmethanone], by the vapour-diffusion method using PEG 6K as precipitant. Crystals diffract to 1.6 Å resolution on a synchrotron-radiation source and belong to the monoclinic space group P21, with unit-cell parameters a = 52.77, b = 79.63, c = 61.54 Å, β = 91.14°. © 2005 International Union of Crystallography All rights reserved.

Cite

CITATION STYLE

APA

Rodrigues, M. L., Bonifácio, M. J., Soares-Da-Silva, P., Carrondo, M. A., & Archer, M. (2005). Crystallization and preliminary X-ray diffraction studies of a catechol-O-methyltransferase/inhibitor complex. Acta Crystallographica Section F: Structural Biology and Crystallization Communications, 61(1), 118–120. https://doi.org/10.1107/S1744309104031197

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free